Publications by authors named "Lavinia Vija-Racaru"
Article Synopsis
- 177 Lu-PSMA-617 (LuPSMA) recently gained EMA approval for treating advanced metastatic castration-resistant prostate cancer, showing potential benefits in earlier disease stages.
- A 77-year-old patient with metastatic prostate cancer developed a rare but severe complication known as therapy-related myelodysplastic syndrome (MDS) with a specific SF3B1 mutation, just one month after his sixth treatment with LuPSMA.
- Despite showing some positive responses in tumor markers and metabolic status, the patient's quality of life was significantly impacted by the onset of MDS.
Dendrogenin A (DDA) is a tumor suppressor mammalian cholesterol-derived metabolite and a new class of ligand of the Liver X receptor (LXR), which displays tumor cell differentiation. In human MCF7 breast adenocarcinoma cells, DDA-induced cell differentiation was associated with an increased accumulation of neutral lipids and proteins found in milk indicating that DDA re-activates some functions of lactating cells. Active iodide transport occurs in the normal lactating mammary cells through the sodium/iodide symporter (NIS) and iodide (I) is secreted into milk to be used by the nursing newborn for thyroid hormones biosynthesis.
View Article and Find Full Text PDFA 58-year-old woman with 5-year history of grade 1 progressive metastatic intestinal neuroendocrine tumor with metachronous liver metastases initially treated by surgery and liver embolization underwent Ga-DOTANOC PET/CT before Lu-DOTATATE therapy. Ga-DOTANOC PET/CT revealed increased uptake in several liver metastases and right iliac lymph nodes, consistent with radiopeptide therapy, including a hypodense isthmic thyroid nodule. Fine needle ultrasound-guided biopsy of the thyroid nodule was realized.
View Article and Find Full Text PDFArticle Synopsis
- An 85-year-old man with a history of treated prostate cancer presented with rising PSA levels, indicating potential cancer recurrence.
- F-choline PET/CT scans revealed not only local recurrence in the prostate but also suspicious thyroid nodules and cervical lymph nodes, suggesting thyroid cancer.
- Subsequent biopsies confirmed that these thyroid nodules and lymph nodes were actually metastatic prostate cancer, leading to a change in disease staging and the initiation of chemotherapy.
Purpose: This study aims to predict hematological toxicity induced by Ra therapy. We investigated the value of metabolically active bone tumor volume (MBTV) and total bone lesion activity (TLA) calculated on pretreatment fluorine-18-fluorocholine (F-FCH) PET/CT in castrate-resistant prostate cancer (CRPC) patients with bone metastases treated with Ra radionuclide therapy.
Patients And Methods: F-FCH PET/CT imaging was performed in 15 patients with CRPC before treatment with Ra.
Unlabelled: Radioiodine is a therapeutic option in Europe for Graves' disease (GD) and toxic multinodular goiter (MNG).
Purpose: To compare empiric and calculated I activities using 2013 EANM recommendations. To look for predictive factors of therapeutic response to an empiric activity of I.